Quoin Pharmaceuticals, Ltd. (QNRX)
Quoin Pharmaceuticals, Ltd. operates in the Biotechnology industry of the Healthcare sector, headquartered in Ashburn, VA, US. The stock last traded at $5.29, up 1.54% on the session, giving a market capitalisation of $10.6M. On trailing twelve-month figures it carries a trailing P/E of -0.30, a net margin of 0.0%. Its beta of 1.66 implies it has historically moved more than the broad market.
Quoin Pharmaceuticals, Ltd. operates as a specialized pharmaceutical firm, concentrating its efforts on devising therapeutic solutions for rare and orphan medical conditions. Its flagship offering, QRX003, is a topical lotion specifically formulated to address Netherton Syndrome. Furthermore, the company is advancing QRX004 for the management of dystrophic epidermolysis bullosa, alongside QRX006, a prospective therapy for an additional rare dermatological ailment. The organization maintains its operational base in Ashburn, Virginia.
Quoin Pharmaceuticals, Ltd. is most often compared with the following Healthcare names: